PSAT1 Regulated Oxidation-Reduction Balance Affects the Growth and Prognosis of Epithelial Ovarian Cancer

Introduction A growing number of studies have found that the serine-glycine biosynthesis pathway is highly activated for biosynthesis in cancer progression and metastasis. Phosphoserine aminotransferase 1 (PSAT1) catalyzes the second step of the serine-glycine biosynthesis pathway; the effects and mechanism of PSAT1 in epithelial ovarian cancer (EOC) remains unclear. Materials and Methods The expression of PSAT1 in clinical EOC samples and normal ovarian tissues was conducted by RT-PCR, Western blot, and immunohistochemical staining. Survival analysis of PSAT1 in ovarian cancer was performed by using the public database. Following the downregulation of PSAT1, the cell growth, cell apoptosis, and cell cycle in ovarian cancer cells were respectively examined by the soft agar colony formation assay and flow cytometry analysis. Then the glutathione (GSH) levels, the GSH/GSSG ratio, the NADPH/NADP ratio, and the cellular reactive oxygen species (ROS) levels were tested to analyze the oxidation-reduction balance in PSAT1-depleted ovarian cancer cells. Results PSAT1 is markedly over-expressed in clinical EOC samples (n = 90) compared to that in normal ovarian tissues (n = 10), and the expression of PSAT1 is correlated with histological subtype, FIGO stage, histological grade, lymph node metastasis, distant metastasis and the presence of ascites. Public database analysis shows that higher PSAT1 indicates poor survival in EOC patients. Downregulation of PSAT1 in EOC cells inhibits growth, induces apoptosis and cell cycle arrest in vitro. EOC cells with high PSAT1 levels have increased a higher GSH (reduced glutathione)/GSSG (oxidized glutathione) ratio and lower reactive oxygen species (ROS) content. The cancer-killing effects of PSAT1 knockdown are reversed by exogenous glutathione. PSAT1 participates in cancer growth by regulating oxidation-reduction balance. Conclusion Therefore, these results highlight the potential of PSAT1 inhibitors or metabolic substrate deprivation as therapeutic strategies for treating patients with EOC, especially those with advanced stages of cancer.

[1]  H. Ahsan,et al.  Understanding oxidants and antioxidants: Classical team with new players. , 2020, Journal of food biochemistry.

[2]  J. Massagué,et al.  Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism , 2020, Molecular Cancer Research.

[3]  Jianguo Fang,et al.  Sanguinarine as a new chemical entity of thioredoxin reductase inhibitor to elicit oxidative stress and promote tumor cell apoptosis. , 2020, Free radical biology & medicine.

[4]  Yunhao Wu,et al.  A cancer-specific activatable theranostic nanodrug for enhanced therapeutic efficacy via amplification of oxidative stress , 2020, Theranostics.

[5]  Lara E Sucheston-Campbell,et al.  Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Park,et al.  Knock-down of PSAT1 Enhances Sensitivity of NSCLC Cells to Glutamine-limiting Conditions , 2019, AntiCancer Research.

[7]  Honglei Chen,et al.  ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer , 2019, Cell Research.

[8]  Elena Butturini,et al.  Natural Sesquiterpene Lactones Enhance Chemosensitivity of Tumor Cells through Redox Regulation of STAT3 Signaling , 2019, Oxidative medicine and cellular longevity.

[9]  Nazarul Hasan,et al.  Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer , 2019, Clinical & Experimental Metastasis.

[10]  Xiao Li,et al.  Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments , 2019, Journal of cellular physiology.

[11]  N. Traverso,et al.  MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance , 2019, Oxidative medicine and cellular longevity.

[12]  Lijiang Hu,et al.  Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy , 2019, Oxidative medicine and cellular longevity.

[13]  B. Kong,et al.  Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway , 2019, Journal of Translational Medicine.

[14]  P. Durrenberger,et al.  mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-β1–induced collagen biosynthesis , 2019, Science Signaling.

[15]  J. Khan,et al.  EWS‐FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine‐glycine biosynthesis , 2018, Molecular carcinogenesis.

[16]  T. Cotter,et al.  Seminars in Cell & Developmental Biology , 2018 .

[17]  Anmei Deng,et al.  Identification and validation of PSAT1 as a potential prognostic factor for predicting clinical outcomes in patients with colorectal carcinoma , 2017, Oncology letters.

[18]  T. Yen,et al.  Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non–Small Cell Lung Cancer Cells , 2017, Molecular Cancer Therapeutics.

[19]  O. Feron,et al.  Challenges and Opportunities in the Development of Serine Synthetic Pathway Inhibitors for Cancer Therapy. , 2017, Journal of medicinal chemistry.

[20]  G. Georgiou,et al.  Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth , 2016, Nature Medicine.

[21]  H. Jang,et al.  Psat1-Dependent Fluctuations in α-Ketoglutarate Affect the Timing of ESC Differentiation. , 2016, Cell metabolism.

[22]  Mohit Mazumder,et al.  Structural investigation and inhibitory response of halide on phosphoserine aminotransferase from Trichomonas vaginalis. , 2016, Biochimica et biophysica acta.

[23]  Xunjia Cheng,et al.  Artemether Exhibits Amoebicidal Activity against Acanthamoeba castellanii through Inhibition of the Serine Biosynthesis Pathway , 2015, Antimicrobial Agents and Chemotherapy.

[24]  P. Mischel,et al.  Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. , 2015, The Journal of clinical investigation.

[25]  H. Guan,et al.  PSAT1 regulates cyclin D1 degradation and sustains proliferation of non‐small cell lung cancer cells , 2015, International journal of cancer.

[26]  I. Amelio,et al.  Serine and glycine metabolism in cancer☆ , 2014, Trends in biochemical sciences.

[27]  A. Papageorgiou,et al.  Structural basis of L-phosphoserine binding to Bacillus alcalophilus phosphoserine aminotransferase. , 2013, Acta crystallographica. Section D, Biological crystallography.

[28]  S. Pignata,et al.  Chemotherapy in epithelial ovarian cancer. , 2011, Cancer letters.

[29]  A. Bolton,et al.  Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia and Autism , 2010, Current genomics.

[30]  A. Cassaigne,et al.  Phosphoserine Aminotransferase, the Second Step‐Catalyzing Enzyme for Serine Biosynthesis , 1999, IUBMB life.